News
For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...
A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol ...
The Clean Label Project tested store-bought coffee and found it is mostly free of harmful levels of toxins and contaminants, ...
The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...
The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...
Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...
Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...
PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic ...
A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...
The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback